Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and 5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine

moxifloxacin has been researched along with 5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine in 1 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine)		Trials
(5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine)		Recent Studies (post-2010) (5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine)
3,1575521,690802

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine (IC50)
Replicase polyprotein 1abBetacoronavirus England 16
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus6
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus6
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 26

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW1

Other Studies

1 other study(ies) available for moxifloxacin and 5-(4-Chloro-benzenesulfonyl)-pyrimidine-2,4-diamine

ArticleYear
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
    Journal of medicinal chemistry, 2021, 12-09, Volume: 64, Issue:23

    Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors

2021